Fox Jonathan C. - 01 Jul 2026 Form 4 Insider Report for Edgewise Therapeutics, Inc. (EWTX)

Reporting relationship: Director
Issuer ticker: EWTX
Reported as of: 01 Jul 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 01 Jul 2026, 19:46:25 UTC
Prior SEC filing: 16 Jun 2026
Source filing: View source filing
Reporting owner signature: /s/ John R. Moore, Attorney-in-Fact for Fox Jonathan C

Key filing fact

Fox Jonathan C. filed Form 4 for Edgewise Therapeutics, Inc. (EWTX) on 01 Jul 2026.

Key facts

This page summarizes Fox Jonathan C.'s Form 4 filing for Edgewise Therapeutics, Inc. (EWTX).
1 reported transaction and 0 derivative rows are listed below.
Accepted by SEC: 01 Jul 2026, 19:46.

Change

Previous filing in this sequence was filed on 16 Jun 2026.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001655016 Primary reporting owner

Fox Jonathan C

Relationship: Director
Address: C/O EDGEWISE THERAPEUTICS, INC., 1715 38TH STREET, BOULDER
Signature: /s/ John R. Moore, Attorney-in-Fact for Fox Jonathan C
Signature date: 01 Jul 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

EWTX transaction

Common Stock

Award

Transaction value
Shares: +319
Change %: +1.3%
Price: $0.000000^*
Shares after: 24,833
Date: 01 Jul 2026
Ownership: Direct

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

SEC remarks

Consists of restricted stock units granted and released to the reporting person on July 1, 2026, as a Quarterly Retainer Award pursuant to Section 2.4 of the Edgewise Therapeutics, Inc. Outside Directors Compensation Policy, as amended.